Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 6 | 2022 | 948 | 1.320 |
Why?
|
| Bone Neoplasms | 6 | 2022 | 2652 | 0.900 |
Why?
|
| Metastasectomy | 2 | 2020 | 208 | 0.780 |
Why?
|
| Mullerian Ducts | 1 | 2015 | 78 | 0.470 |
Why?
|
| Vagina | 1 | 2015 | 332 | 0.430 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 11816 | 0.390 |
Why?
|
| Uterus | 1 | 2015 | 699 | 0.360 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2017 | 349 | 0.350 |
Why?
|
| Thoracoscopy | 2 | 2020 | 103 | 0.350 |
Why?
|
| Thoracotomy | 2 | 2020 | 225 | 0.330 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 1018 | 0.320 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 645 | 0.290 |
Why?
|
| Kidney | 1 | 2015 | 2196 | 0.270 |
Why?
|
| Databases, Factual | 9 | 2019 | 2316 | 0.260 |
Why?
|
| Wilms Tumor | 2 | 2018 | 295 | 0.240 |
Why?
|
| Neuroblastoma | 2 | 2020 | 695 | 0.230 |
Why?
|
| Pneumoperitoneum | 1 | 2023 | 17 | 0.220 |
Why?
|
| Thyroidectomy | 2 | 2017 | 492 | 0.220 |
Why?
|
| Child | 21 | 2023 | 30149 | 0.210 |
Why?
|
| Adolescent | 21 | 2020 | 32284 | 0.200 |
Why?
|
| Specialties, Surgical | 1 | 2023 | 142 | 0.190 |
Why?
|
| Ketones | 2 | 2018 | 56 | 0.190 |
Why?
|
| Furans | 2 | 2018 | 106 | 0.190 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 9002 | 0.190 |
Why?
|
| United States | 13 | 2020 | 16312 | 0.180 |
Why?
|
| Registries | 3 | 2018 | 2278 | 0.180 |
Why?
|
| Health Care Surveys | 1 | 2020 | 444 | 0.160 |
Why?
|
| Retrospective Studies | 18 | 2020 | 39457 | 0.160 |
Why?
|
| Dysgerminoma | 1 | 2017 | 44 | 0.150 |
Why?
|
| Ovarian Neoplasms | 3 | 2018 | 4730 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 56 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 666 | 0.130 |
Why?
|
| Nephrectomy | 2 | 2018 | 787 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 79 | 0.130 |
Why?
|
| Sarcoma | 2 | 2017 | 1830 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 418 | 0.130 |
Why?
|
| Fertility Preservation | 1 | 2017 | 156 | 0.130 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 5114 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2019 | 16762 | 0.130 |
Why?
|
| Spinal Injuries | 1 | 2015 | 33 | 0.130 |
Why?
|
| Carcinoma | 3 | 2016 | 2601 | 0.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 1888 | 0.130 |
Why?
|
| Humans | 32 | 2023 | 270303 | 0.120 |
Why?
|
| Infant | 10 | 2023 | 13785 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 646 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2017 | 271 | 0.120 |
Why?
|
| Infant, Newborn | 9 | 2023 | 8546 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2015 | 170 | 0.120 |
Why?
|
| Rhabdomyosarcoma | 1 | 2017 | 346 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1716 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 217 | 0.120 |
Why?
|
| Female | 26 | 2020 | 146977 | 0.110 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 326 | 0.110 |
Why?
|
| Young Adult | 11 | 2020 | 22092 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 3097 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 179 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 553 | 0.110 |
Why?
|
| Parathyroidectomy | 1 | 2014 | 208 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 186 | 0.110 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 620 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 649 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2015 | 679 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 1384 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 441 | 0.100 |
Why?
|
| Prognosis | 10 | 2019 | 22228 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2023 | 1472 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2730 | 0.100 |
Why?
|
| Survival Rate | 7 | 2019 | 12429 | 0.100 |
Why?
|
| Syndrome | 1 | 2015 | 1382 | 0.100 |
Why?
|
| Survival Analysis | 6 | 2019 | 9322 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2017 | 7156 | 0.100 |
Why?
|
| Male | 22 | 2020 | 127343 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2020 | 13265 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 10254 | 0.090 |
Why?
|
| Torsion Abnormality | 1 | 2010 | 39 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 1228 | 0.090 |
Why?
|
| Adenoma | 1 | 2014 | 732 | 0.090 |
Why?
|
| Age Distribution | 3 | 2016 | 715 | 0.090 |
Why?
|
| Omentum | 1 | 2010 | 97 | 0.080 |
Why?
|
| Appendicitis | 1 | 2010 | 173 | 0.080 |
Why?
|
| Age Factors | 4 | 2019 | 5489 | 0.080 |
Why?
|
| Adult | 13 | 2019 | 80561 | 0.080 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 13879 | 0.080 |
Why?
|
| Patient Selection | 1 | 2015 | 2114 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 1429 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 1240 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2010 | 374 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 10092 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6269 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2338 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 15176 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2019 | 34144 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1263 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5228 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 4073 | 0.050 |
Why?
|
| Abdomen | 1 | 2023 | 337 | 0.050 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 44 | 0.050 |
Why?
|
| Incidence | 3 | 2016 | 5886 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7903 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 4775 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 9471 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5444 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 133 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 2019 | 27 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4774 | 0.040 |
Why?
|
| Gestational Age | 1 | 2023 | 1082 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7733 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 156 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2020 | 745 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 4052 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14497 | 0.040 |
Why?
|
| Surgical Oncology | 1 | 2020 | 192 | 0.040 |
Why?
|
| Pediatrics | 2 | 2017 | 1186 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2023 | 818 | 0.040 |
Why?
|
| Neoplasms | 1 | 2023 | 15695 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 4384 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 16258 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 1998 | 198 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2017 | 105 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 325 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 246 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1025 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 1997 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2019 | 700 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2015 | 251 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 1569 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 231 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2019 | 680 | 0.030 |
Why?
|
| Aged | 5 | 2019 | 72685 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 1978 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 172 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 568 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 796 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 510 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 4849 | 0.030 |
Why?
|
| Middle Aged | 5 | 2019 | 89347 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1354 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 16050 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1998 | 646 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2214 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 590 | 0.020 |
Why?
|
| SEER Program | 1 | 2014 | 1012 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1102 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 18226 | 0.020 |
Why?
|
| Appendectomy | 1 | 2010 | 126 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4925 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 2015 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 1347 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 30718 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 2472 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5292 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5816 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2010 | 1258 | 0.010 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1998 | 102 | 0.010 |
Why?
|
| Obesity | 1 | 2010 | 2989 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 506 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 982 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1998 | 1925 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 5115 | 0.010 |
Why?
|
| Time Factors | 1 | 1998 | 13246 | 0.000 |
Why?
|